Prediction of ESR1 Network and Molecular Modeling Analysis of Bioactive Molecules from Ficus microcarpa Targeting ER-alpha for Breast Cancer Therapy

被引:0
|
作者
Chandran, Kaliraj [1 ]
Zochedh, Azar [1 ,2 ]
Rawat, Ravi [3 ]
Eyupoglu, Volkan [4 ]
Sultan, Asath Bahadur [5 ]
Kathiresan, Thandavarayan [1 ]
机构
[1] Kalasalingam Acad Res & Educ, Dept Biotechnol, Krishnankoil 626126, Tamil Nadu, India
[2] Ctr Mol Simulat, Biomaz Infosearch, Tamil Nadu 625706, India
[3] UPES Univ, Sch Hlth Sci Technol, Dehra Dun 248007, India
[4] Cankiri Karatekin Univ, Dept Chem, TR-18100 Cankiri, Turkiye
[5] Kalasalingam Acad Res & Educ, Dept Phys, Int Res Ctr, Condensed Matter Phys Lab, Krishnankoil 626126, India
关键词
Ficus microcarpa; Breast cancer; Molecular docking; DFT; Molecular dynamic simulation; ESTROGEN-RECEPTORS; DYNAMICS; ALGORITHM; MODULATOR; BETA;
D O I
10.1007/s42250-024-01148-1
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Ficus microcarpa L. f. is a common tree found in India, as well as South, Southeast, and East Asia, and is known locally as Kallichi maram (Tamil). The major phytochemicals from F. microcarpa have anti-cancer properties. This study focusses on analysing the network of target estrogen receptor (ESR1), a hormonal-receptor linked to breast cancer with its functional genes. The greater scores of binding energies was observed with friedelin, epifriedelanol, and taraxerol with -10.2, -9.8, and -9.6 kcal/mol. The band gap energies of these three compounds were calculated based on molecular orbitals confirming the structural stability. The electrophilic and nucleophilic attacks on the friedelin, epifriedelanol, and taraxerol were identified through electrostatic surface potential. The lead compounds' physicochemical and pharmacokinetic characteristics proved their better biocompatibility and safety profile. Molecular dynamic simulation for a time-period of 100 nanoseconds revealed the complex structure of target ER alpha with friedelin, epifriedelanol, and taraxerol were stable in the biological environment. The protein backbone showed very minimal deviation and fluctuation of amino acids after binding with top hit ligands friedelin, epifriedelanol, and taraxerol. The computational results suggest that these findings can be beneficial in the development of chemotherapeutic agent against luminal type breast cancer by targeting estrogen receptor-alpha.
引用
收藏
页码:167 / 186
页数:20
相关论文
共 7 条
  • [1] Vaccines targeting ESR1 activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER plus breast cancer
    Dailey, Gabrielle P.
    Rabiola, Christopher A.
    Lei, Gangjun
    Wei, Junping
    Yang, Xiao-Yi
    Wang, Tao
    Liu, Cong-Xiao
    Gajda, Melissa
    Hobeika, Amy C.
    Summers, Amanda
    Marek, Robert D.
    Morse, Michael A.
    Lyerly, Herbert K.
    Crosby, Erika J.
    Hartman, Zachary C.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [2] Detection of ESR1 mutations in plasma cell-free DNA from metastatic ER-positive breast cancer patients resistant to hormone therapy
    Masotti, Cibele
    Knebel, Franciele H.
    Linck, Rudinei D. M.
    Lima, Julianne
    Shimada, Andrea K.
    Alessi, Joao Victor
    Zucchetti, Bruna M.
    Kleftogiannis, Dimitrios
    Barber, Louise
    Gerlinger, Marco
    Katz, Artur
    Mano, Max S.
    Camargo, Anamaria A.
    Bettoni, Fabiana
    CLINICAL CANCER RESEARCH, 2020, 26 (11) : 43 - 44
  • [3] Analysis of ESR1 Mutations in Single Circulating Tumor Cells from Metastatic Luminal Breast Cancer Patients Upon Estrogen Deprivation Therapy
    Franken, Andre
    Honisch, Ellen
    Reinhardt, Florian
    Meier-Stiegen, Franziska
    Yang, Liwen
    Alberter, Barbara
    Polzer, Bernhard
    Niederacher, Dieter
    Fehm, Tanja
    Neubauer, Harts
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 21 - 22
  • [4] Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients
    Takeshita, Takashi
    Yamamoto, Yutaka
    Yamamoto-Ibusuki, Mutsuko
    Tomiguchi, Mai
    Sueta, Aiko
    Murakami, Keiichi
    Omoto, Yoko
    Iwase, Hirotaka
    ONCOTARGET, 2017, 8 (32) : 52142 - 52155
  • [5] Pterostilbene as a potent ESR-1 in breast cancer therapy: insights from network pharmacology, molecular docking, dynamics simulations, ADMET, and in vitro analysis
    Marwah, Harneet
    Dewangan, Hitesh Kumar
    MOLECULAR DIVERSITY, 2025,
  • [6] Serial analysis of ESR1 and PIK3CA mutations in cell-free DNA from metastatic breast cancer during 1st line endocrine therapy
    Baek, Soo Yeon
    Hong, Meehyang
    Lee, Seungah
    Joo, Seulgi
    Jang, JungPil
    Jung, Chinkoo
    Lee, Sae Byul
    Yoo, Tae-Kyung
    Chung, Il Yong
    Kim, Hee Jeong
    Ko, Beom Seok
    Lee, Jong Won
    Son, Byung Ho
    Jeong, Hyehyun
    Jeong, Jae Ho
    Ahn, Jin-Hee
    Jung, Kyung Hae
    Kim, Sung-Bae
    Lee, Hee Jin
    Kim, Jisun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis by prior duration of CDK4/6i plus endocrine therapy (ET)
    Kaklamani, Virginia G.
    Bidard, Francois Clement
    Neven, Patrick
    Montero, Alberto J.
    Mouret-Reynier, Marie-Ange
    Sohn, Joohyuk
    Taylor, Donatienne
    Forget, Frederic
    Harnden, Kathleen Kiernan
    Khong, Hung T.
    Kocsis, Judit
    Dalenc, Florence
    Dillon, Patrick Michael
    Waters, Simon
    Garcia-Saenz, Jose A.
    Aftimos, Philippe Georges
    Cortes, Javier
    Scartoni, Simona
    Habboubi, Nassir
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)